文献速递胰腺与胆道疾病

胰腺炎活动度评分系统可预测急性胰腺炎的临床结局:一项前瞻性队列研究的结果

The Pancreatitis Activity Scoring System predicts clinical outcomes in acute pancreatitis: findings from a prospective cohort study.
PubMed 文献 · Am J Gastroenterol · 2018-03-15

本研究对2015年3月至2017年3月在洛杉矶县医院连续入院的439例急性胰腺炎患者进行前瞻性队列分析,外部验证胰腺炎活动度评分系统(PASS)。入院PASS评分>140与中重度/重度胰腺炎、ICU入住、局部并发症、SIRS及住院延长相关;出院PASS评分>60与早期再入院相关。PASS对中重度/重度胰腺炎的预测能力与Ranson、Glasgow、Panc3、HAPS评分系统相当。

要点

  • 入院PASS评分>140与中重度/重度胰腺炎相关(OR 3.5,95%CI 2.0-6.3)。
  • 入院PASS评分>140与ICU入住(OR 4.9)、局部并发症(OR 3.0)、SIRS(OR 2.9)及住院延长1.5天相关。
  • 出院PASS评分>60与30天内早期再入院相关(OR 5.0,95%CI 2.4-10.7)。

核心结论

  • PASS评分与急性胰腺炎的重要临床结局相关。
  • 该评分能在疾病不同阶段预测重要临床事件,提示其是评估急性胰腺炎患者活动度的有效指标。

研究设计与样本

  • 研究为前瞻性队列研究,纳入2015年3月至2017年3月间连续入住洛杉矶县医院的患者,共439例,平均年龄42(±15)岁,53%为男性。
  • 通过急诊科传呼系统和电子警报系统识别患者,全面收集物质使用史、胰腺炎病因、生化指标及详细临床过程。
  • 在入院时、出院时及住院期间每12小时计算PASS评分,采用多变量逻辑回归分析入院PASS评分与重症胰腺炎风险的关系,并与已有评分系统比较预测能力。

主要发现

  • 入院PASS评分>140与中重度及重度胰腺炎相关(OR 3.5 [95% CI 2.0, 6.3]),与ICU入住(OR 4.9 [2.5, 9.4])、局部并发症(OR 3.0 [1.6, 5.7])、SIRS发生(OR 2.9 [1.8, 4.5])相关,并使住院时间平均延长1.5(1.3-1.7)天。
  • 对于中重度/重度胰腺炎的预测,PASS评分(AUC=0.71)与Ranson(AUC=0.63)、Glasgow(AUC=0.72)、Panc3(AUC=0.57)和HAPS(AUC=0.54)评分系统相当。
  • 出院PASS评分>60与早期再入院相关(OR 5.0 [2.4, 10.7])。

关键数值与推荐

  • 入院PASS评分>140:中重度/重度胰腺炎OR 3.5(95%CI 2.0-6.3),ICU入住OR 4.9(2.5-9.4),局部并发症OR 3.0(1.6-5.7),SIRS OR 2.9(1.8-4.5),住院延长1.5(1.3-1.7)天。
  • 出院PASS评分>60:早期再入院OR 5.0(95%CI 2.4-10.7)。
  • 预测中重度/重度胰腺炎的AUC:PASS 0.71,Ranson 0.63,Glasgow 0.72,Panc3 0.57,HAPS 0.54。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The Pancreatitis Activity Scoring System (PASS) has been derived by an international group of experts via a modified Delphi process. Our aim was to perform an external validation study to assess for concordance of the PASS score with high face validity clinical outcomes and determine specific meaningful thresholds to assist in application of this scoring system in a large prospectively ascertained cohort. METHODS: We analyzed data from a prospective cohort study of consecutive patients admitted to the Los Angeles County Hospital between March 2015 and March 2017. Patients were identified using an emergency department paging system and electronic alert system. Comprehensive characterization included substance use history, pancreatitis etiology, biochemical profile, and detailed clinical course. We calculated the PASS score at admission, discharge, and at 12 h increments during the hospitalization. We performed several analyses to assess the relationship between the PASS score and outcomes at various points during hospitalization as well as following discharge. Using multivariable logistic regression analysis, we assessed the relationship between admission PASS score and risk of severe pancreatitis. PASS score performance was compared to established systems used to predict severe pancreatitis. Additional inpatient outcomes assessed included local complications, length of stay, development of systemic inflammatory response syndrome (SIRS), and intensive care unit (ICU) admission. We also assessed whether the PASS score at discharge was associated with early readmission (re-hospitalization for pancreatitis symptoms and complications within 30 days of discharge). RESULTS: A total of 439 patients were enrolled, their mean age was 42 (±15) years, and 53% were male. Admission PASS score >140 was associated with moderately severe and severe pancreatitis (OR 3.5 [95% CI 2.0, 6.3]), ICU admission (OR 4.9 [2.5, 9.4]), local complications (3.0 [1.6, 5.7]), and development of SIRS (OR 2.9 [1.8, 4.5]) as well as prolongation of hospitalization by a mean of 1.5 (1.3-1.7) days. For the prediction of moderately severe/severe pancreatitis, the PASS score (AUC = 0.71) was comparable to the more established Ranson's (AUC = 0.63), Glasgow (AUC = 0.72), Panc3 (AUC = 0.57), and HAPS (AUC = 0.54) scoring systems. Discharge PASS score >60 was associated with early readmission (OR 5.0 [2.4, 10.7]). CONCLUSIONS: The PASS score is associated with important clinical outcomes in acute pancreatitis. The ability of the score to forecast important clinical events at different points in the disease course suggests that it is a valid measure of activity in patients with acute pancreatitis.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Buxbaum J, Quezada M, Chong B, et al. The Pancreatitis Activity Scoring System predicts clinical outcomes in acute pancreatitis: findings from a prospective cohort study. Am J Gastroenterol. 2018. PMID: 29545634. doi:10.1038/s41395-018-0048-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。